Replimune Group Inc. is at the forefront of developing innovative oncolytic immunotherapies that aim to address the challenges posed by cancer through a dual mechanism. Their therapies are designed to directly destroy tumors while simultaneously modifying the tumor microenvironment (TME) to release tumor-derived antigens. This process stimulates a robust and lasting systemic immune response against the patient's own cancer. Replimune's approach not only targets tumors effectively as standalone treatments but also enhances the efficacy of other therapeutic modalities, including immunotherapy, chemotherapy, and radiation, leveraging a synergistic immune-mediated strategy.

Central to Replimune's technology is their proprietary RPx platform, which utilizes a modified strain of the herpes simplex virus (HSV-1) known for its ability to selectively target and kill a wide range of human cancer cell types. This platform is engineered to improve tumor specificity and safety, ensuring that the virus primarily affects cancer cells. By incorporating specific therapeutic genes, Replimune's therapies augment the virus's natural tumor-killing capabilities, block mechanisms that dampen immune responses, and provide essential co-stimulatory signals to activate T cells. This comprehensive approach aims to generate a powerful anti-tumor response, positioning Replimune's pipeline of oncolytic immunotherapies as a promising option for patients with various difficult-to-treat cancers.

United States

Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Cancer

Skin Diseases

Replimune Group Inc

Melanoma

Oncolytic immunotherapy is an emerging class of cancer therapeutics that &nbsp;exploits the ability of viruses to selectively replicate in and kill &nbsp;tumors, while at the same time inducing a potent, patient-specific, &nbsp;anti-tumor immune response.&nbsp;
RP1 is Replimune’s lead Immulytic™ product candidate and &nbsp;is based on a proprietary new strain of herpes simplex virus engineered &nbsp;to maximize tumor killing potency, the immunogenicity of tumor cell &nbsp;death and the activation of a systemic anti-tumor immune response through the expression of a GALV-GP R- fusogenic protein and GM-CSF.

RP1 +Opdivo (nivolumab)

Cutaneous squamous cell carcinoma

Oncolytic immunotherapy is an emerging class of cancer therapeutics that &nbsp;exploits the ability of viruses to selectively replicate in and kill &nbsp;tumors, while at the same time inducing a potent, patient-specific, &nbsp;anti-tumor immune response.&nbsp;
RP1 is Replimune’s lead Immulytic™ product candidate and &nbsp;is based on a proprietary new strain of herpes simplex virus engineered &nbsp;to maximize tumor killing potency, the immunogenicity of tumor cell &nbsp;death and the activation of a systemic anti-tumor immune response through the expression of a GALV-GP R- fusogenic protein and GM-CSF.

RP1 + Libtayo (cemiplimab)

Non-melanoma skin cancer

RP1 + Opdivo

Uveal melanoma

RP2 + Opdivo 

Hepatocellular carcinoma

Oncolytic immunotherapy is an emerging class of cancer therapeutics that &nbsp;exploits the ability of viruses to selectively replicate in and kill &nbsp;tumors, while at the same time inducing a potent, patient-specific, &nbsp;anti-tumor immune response.&nbsp;
RP3 expresses the GALV-GP R(-) fusogenic protein, anti-CTLA-4 molecule, CD40L, and 4-1BBL which stimulate an anti-tumor immune response through immune co-stimulatory pathway activation. RP3 is intended to maximize so-called Signal 1 &nbsp;(antigen presentation), Signal 2 (immune &nbsp;co-stimulation) and Signal 3 (the production of inflammatory cytokines, &nbsp;stimulated by CD40L and 4-1BBL).

 RP2 in comb w/ atezolizumab and bevacizumab

Breast cancer

Head and neck cancer

Lung cancer

Solid tumor/s

Oncolytic immunotherapy is an emerging class of cancer therapeutics that &nbsp;exploits the ability of viruses to selectively replicate in and kill &nbsp;tumors, while at the same time inducing a potent, patient-specific, &nbsp;anti-tumor immune response.&nbsp;
RP2 is an enhanced potency oncolytic immunotherapy which &nbsp;expresses an anti-CTLA-4 molecule, intended to improve on the safety and &nbsp;efficacy profile of systemic antibody approaches to targeting CTLA-4, &nbsp;in addition to expressing the GALV-GP R- fusogenic protein and GM-CSF.

Replimune Group Inc

Company Details